Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
- 2 January 2020
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 65 (10) , 2986-2991
Abstract
Patients with inflammatory bowel disease (IBD) are at increased risk of developing herpes zoster. In October 2017, the FDA approved a two-dose adjuvanted, recombinant herpes zoster vaccine (RZV). There is a theoretical concern that vaccine adjuvants may cause flares in patients with immune-mediated diseases. We aimed to assess the rates of IBD flare and adverse reactions after administration of RZV in a cohort of patients with IBD.Keywords
This publication has 27 references indexed in Scilit:
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical TrialsClinical Gastroenterology and Hepatology, 2019
- Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort StudyClinical Gastroenterology and Hepatology, 2018
- Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster VaccinesMMWR. Morbidity and Mortality Weekly Report, 2018
- Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or OlderNew England Journal of Medicine, 2016
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsNew England Journal of Medicine, 2015
- Herpes ZosterNew England Journal of Medicine, 2013
- Increased risk of herpes zoster among 108 604 patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2012
- Varicella zoster virus infection in inflammatory bowel diseaseInflammatory Bowel Diseases, 2012
- Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's DiseaseAmerican Journal of Gastroenterology, 2009
- Incidence and Risk Factors for Herpes Zoster Among Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2006